双模态超声与MRI预测乳腺癌新辅助化疗后病理完全缓解
这项前瞻性两中心研究纳入224例接受新辅助化疗的原发性乳腺癌患者,于术前采集双模态超声(灰阶与剪切波)及MRI数据,以术后病理为参考标准评估uCR、mCR及联合模型。以ypT0/Tis为病理完全缓解标准时,联合影像模型AUC为0.87,优于uCR模型(AUC=0.76,P=.002)和mCR模型(AUC=0.80,P=.04);双模态超声预测效能与MRI相当。
要点
- 双模态超声预测新辅助化疗后病理反应效能与MRI相当,联合US/MRI模型诊断效能高于任一单独模态。
- 以ypT0/Tis为参考时,联合模型AUC=0.87,uCR模型AUC=0.76,mCR模型AUC=0.80。
- 以ypT0为参考时,联合模型AUC=0.87,uCR模型AUC=0.79,mCR模型AUC=0.75。
核心结论
- 双模态超声能有效预测乳腺癌新辅助化疗后的病理反应,准确性与MRI相当;联合US/MRI模型诊断效能高于任一单独模态。
研究设计与样本
- 前瞻性两中心研究,纳入2020年1月至2024年1月期间接受新辅助化疗的原发性乳腺癌女性224例,中位年龄46岁(IQR 38.75-56)。
- 术前采集双模态超声(灰阶与剪切波)及MRI数据,由放射科医师定义超声完全缓解(uCR)与MRI完全缓解(mCR),以术后病理为参考标准。
- 病理完全缓解定义为无残留肿瘤(ypT0)或无浸润性癌但可能伴导管原位癌(ypT0/Tis),采用AUC评估模型效能并用DeLong检验比较,所有检验为双侧(P<.05)。
诊断标准与关键数值
- 以ypT0/Tis为病理完全缓解标准:uCR模型AUC=0.76(95%CI: 0.67, 0.83),mCR模型AUC=0.80(95%CI: 0.71, 0.87)。
- 以ypT0为病理完全缓解标准:uCR模型AUC=0.79(95%CI: 0.70, 0.86),mCR模型AUC=0.75(95%CI: 0.65, 0.82)。
- 联合影像模型以ypT0/Tis为参考时AUC=0.87,以ypT0为参考时AUC=0.87,均优于uCR模型(ypT0/Tis P=.002;ypT0 P=.002)和mCR模型(ypT0/Tis P=.04;ypT0 P=.004)。
- 全组224例中82例(37%)达到ypT0/Tis,62例(28%)达到ypT0。
临床应用与阅片要点
- 阅片时可同时参考术前双模态超声(灰阶与剪切波)与MRI的完全缓解判断,联合模型较任一单独模态提供更高的诊断效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine whether bimodal US improves prediction of pathologic complete response following neoadjuvant chemotherapy (NAC) compared with MRI, as well as to assess the diagnostic value of a combined imaging model. Materials and Methods In this prospective two-center study, participants with primary breast cancer undergoing NAC between January 2020 and January 2024 were enrolled. Preoperative bimodal US (grayscale and shear wave) and MRI data were collected. Complete response on US (uCR) and MR images (mCR) were defined by radiologists. Diagnostic models based on uCR, mCR, and their combination were evaluated using postsurgical pathology as the reference standard. Pathologic complete response was defined as no residual tumor (ypT0) or no invasive cancer with possible ductal carcinoma in situ (ypT0/Tis). Model performance was evaluated by area under the receiver operating characteristic curve (AUC), with sensitivity, specificity, positive and negative likelihood ratios, and comparisons by the DeLong test. All tests were two-sided (P < .05). Results A total of 224 female participants (median age, 46 years; IQR, 38.75-56) with breast cancer undergoing NAC were included. Overall, 82 of 224 (37%) achieved ypT0/Tis, and 62 of 224 (28%) achieved ypT0. Using ypT0/Tis as the pathologic complete response standard, the uCR model achieved an AUC of 0.76 (95% CI: 0.67, 0.83), while the mCR model achieved an AUC of 0.80 (95% CI: 0.71, 0.87). Using ypT0, the uCR model achieved an AUC of 0.79 (95% CI: 0.70, 0.86), and the mCR model an AUC of 0.75 (95% CI: 0.65, 0.82) in the test set. The combined imaging model (ypT0/Tis, AUC = 0.87; ypT0, AUC = 0.87) outperformed both the uCR (ypT0/Tis, P = .002; ypT0, P = .002) and mCR models (ypT0/Tis, P = .04; ypT0, P = .004). Conclusion Bimodal US effectively predicted pathologic response to NAC in breast cancer with accuracy comparable to MRI. A combined US/MRI model demonstrated higher diagnostic performance than either modality alone. Keywords: Breast, Ultrasound Chinese Clinical Trial Registry (ChiCTR2400085035) Supplemental material is available for this article. © RSNA, 2025 See also commentary by Horvat and Fazzio in this issue.
引用
- Wang XY, Huang JX, Liu FT, et al. Predicting Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy Using Bimodal US and MRI. Radiol Imaging Cancer. 2025. PMID: 41104975. doi:10.1148/rycan.240493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。